Collectively, these biological effects induced by mitazalimab align with the hypothesized mechanism of anti-tumor activity for a CD40 agonist when combined with chemotherapy and support the treatment approach implemented in the OPTIMIZE-1 trial. The gene discussed is CD40; the disease is neoplasm.